Dear BSBMTCT member,

As we approach the end of a quite remarkable year, we want to take a moment to thank each of you for your commitment, expertise and generosity. Our Society exists to improve patient outcomes – both survival and quality of life – by advancing the fields of blood and marrow transplantation and cellular therapy — and none of what has been achieved would be possible without your involvement. Thank You!

A year of progress and collaboration

 2025 has been the first full year of our Strategic Plan (2025 – 2030), and we have worked to lay the foundations for our future work together, exploring how we can better fulfil our purpose and do and provide more to meet members’ needs. We have sought to be truly collegiate and have taken a more strategic and proactive approach to the forging of mutually beneficial alliances that will further enhance our impact and the Society’s ability to fulfil its purpose into the future. We were thrilled to launch our strategic partnership with Anthony Nolan, working together to:

• Improve patient outcomes and experience;
• Strengthen the UK’s ecosystem for transplantation and cell therapies;
• Enable more effective collection, analysis and use of data;
• Support joint fundraising, advocacy, and research activities;
• Enhance the long-term sustainability and organisational resilience of both Parties.

Together Anthony Nolan and BSBMTCT have been working up a number of domains for collaboration which include:

• Registry and data development
• Research Enablement
• Education and training
• Policy, Advocacy, and Influencing
• Commercial and Business Development
• Operational support

UK Stem cell Strategic Forum (UKSCSF) Data Commission

 We have worked proactively with the UKSCSF Data Commissioners and Anthony Nolan to agree how we explore the development a bespoke UK transplant and cell therapy registry – with greater breadth and granularity of data. We believe we need high-quality HSCT and cell-based ATMP datasets to improve outcomes and drive innovation enabling:

• Real-time identification of clinical improvements – that enhance patient outcomes, experience and quality of life
• R&D investment from the global Life Sciences sector

Working with partners, we hope during 2026 to develop a comprehensive and stakeholder-informed Registry Proposition and Business Case, incorporating a:

• Vision and value proposition.
• Detailed requirements specification.
• Implementation roadmap.
• Investment case with costs and benefits.
• Governance and delivery model recommendations.

Income diversification and growth

During the year the Trustees developed a Pricing Policy guiding the process of data sharing with commercial partners. We are pleased to have now worked with three pharma partners to provide them with aggregated data. This has contributed to a growth in our income which we hope will enable the Society over time to increase our capacity and membership services.

We look forward to working with new partners in 2026.

Other highlights of 2025

 Other highlights of this last year include:

• The successful delivery of our Education and Scientific Days, and our Advanced Cellular Therapy showcase. Our annual events brought together members from across the UK and Republic of Ireland, showcasing research from national and international thought leaders. The feedback has been overwhelmingly positive, and planning for next year is already underway.
• Our 8^th year of delivering our popular and well attended Data Management training day, providing:
  • updates from both BSBMTCT and EBMT;
  • training and tips on the EBMT registry;
  • world leading clinical input

This annually event supports data and quality management staff from across UK and Republic of Ireland.

• The expansion of our BSBMTCT Induction Manual with new modules and sections on our E-learning platform. New sections were launched specifically for Quality Managers this year
• The appointment of Francis Adams as our full-time Senior Medical Statistician
• High level support by the registry team in developing and improving the EBMT registry, including the writing of the EBMT HLA data entry manual.
• Austin Kulasekararaj’s presentation of BSBMTCT data on FCC transplantation as an oral at the 2025 American Society of Haematology meeting (ASH); Excellent long-term outcomes after alemtuzumab-based hematopoietic cell transplantation (HCT) for severe aplastic anaemia (SAA) and inherited bone marrow failure syndromes (IBMF): A 25-year British society of blood and marrow transplantation and cellular therapy (BSBMTCT) retrospective analysis of 1754 patients from the United Kingdom (UK)
• Representation of BSBMTCT and other national registries on the EBMT Registry Committee
• 2024 activity published on our website, https://bsbmtct.org/2024-activity/
• Relationships formed with potential new partners
• Playing a leading role in the work of the Federation of Clinical Registries
• Working with our community to publish the rapid guideline for the UK Clinical Community Consensus on the emerging use of PTCy
• Publication of a range of guidelines. https://bsbmtct.org/guidelines-sub-committee/
• Two successful meetings of the BSBMTCT Clinical Trials Sub Committee (CTSC), where several new retrospective studies and surveys were approved, alongside the publication of a number of papers, including the first of 3 papers in the Teenage and Young Adults (TYA) cohort, the Cryopreservation Study, as well as two papers in the Multiple Sclerosis (MS) group
• Presentation by our Interim Chief Executive on the importance of collaborative working at the IMPACT Day in October 2025
• Publication of the workforce recommendations by the Paediatric Group
• Strengthened governance through the approval of a Risk Register, Scheme of Delegation, Business Continuity Plan, and Reserves Policy. These documents support our transition towards becoming a modern, executive lead Society
• The appointment of a world-wide legal firm providing advice and guidance on a pro-bono basis
• Preparations for the appointment of a permanent Chief Executive
• A major contribution towards the All-Party Parliamentary Group (APPG) for Ethnicity Transplantation and Transfusion

 During the year we were delighted that members of our community were elected to the following roles:

Indications SC Chair                                Rachel Protheroe

Clinical Trials SC Co-Chairs                   Pramila Krishnamurthy and Anjum Khan

Vaccination & Infection SC Chair         Reem Elfeky

We are very grateful to everyone who has been willing to lead and serve on our committees and sub-committee. We look forward to further collaborative working together in 2026.

Meeting Grant Round

As 2025 draws to an end, we also want to remind you that our BSBMTCT Meetings Grant Round for EBMT 2026 is still open until 5pm on Sunday 28^th December 2025.  All information including official communication, application form and handbook can also be found on the BSBMTCT website: https://bsbmtct.org/bsbmtct-meeting-grants/  Please send all applications to Julia.lee@kcl.ac.uk.  We are unable to accept late applications.

16^th Commissioners Report

Work on the 16^th Edition of BSBMTCT Executive Summary of Transplant & Cellular Therapy Outcomes in UK and ROI is underway but we apologise that progress has been slower than expected. We have been working to overcome problems with the new EBMT database and hope to deliver the reports early in 2026. We will keep you updated on progress. If you have any questions, please direct them to the Head of Registry, Julia Lee on julia.lee@kcl.ac.uk

BSBMTCT Dates for your Diary for 2026

•  BSBMTCT Scientific Day – Wednesday 6^th May 2026
• BSBMTCT Scientific Showcase – Friday 19^th June 2026
• BSBMTCT Education Day – Thursday 5^th November 2026

Season’s Greetings

 On behalf of the Society, we want to wish you a peaceful Christmas and a restorative break. Thank you for everything you do — for your patients, your colleagues, and for the advancement of our field. We look forward to working with you in 2026.

 Our Very Best Wishes, Deborah Richardson, Eduardo Olavarria, Fiona Dignan, Harpreet Kaur, Victoria Potter, David Reynolds & Julia Lee